CN104231099A - Inulin zinc and oral liquid containing same - Google Patents
Inulin zinc and oral liquid containing same Download PDFInfo
- Publication number
- CN104231099A CN104231099A CN201410444786.6A CN201410444786A CN104231099A CN 104231099 A CN104231099 A CN 104231099A CN 201410444786 A CN201410444786 A CN 201410444786A CN 104231099 A CN104231099 A CN 104231099A
- Authority
- CN
- China
- Prior art keywords
- zinc
- inulin
- oral liquid
- liquid containing
- weight part
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses inulin zinc and oral liquid which contains the same. The inulin zinc is prepared by alkalifying and etherifying inulin and then chelating with a zinc ion. The oral liquid comprises the inulin zinc, a buffering agent, a sweetening agent and water, wherein the content of the inulin zinc is 2400-11000 mg/L. The oral liquid which contains the inulin zinc contains no additive, is capable of supplementing zinc and enhancing the absorption of a human body on zinc and has the advantages of good zinc supplementation effect and the like, and is beneficial to human health.
Description
Technical field
The present invention relates to field of food health care, specifically provide inulin zinc and the oral liquid containing inulin zinc.
Background technology
Zinc is one of trace element of needed by human, and needed for the content in human body and every day, intake is all little, but plays very important effect to growing of body.Human normal zinc content is 2-3 gram, and have the zinc of denier to distribute in most tissues, wherein liver, muscle and bone content are higher.Containing visual component (containing 4%) and prostate gland that the tissue that zinc is the highest is eyeball.Contain the enzyme of zinc in human body and reached kind more than 70 by the enzyme that zinc activates.Zinc participates in the metabolic process of nucleic acid protein, can promote the normal development of skin, bone, brain and sexual organ, maintains digestion and metabolism movable; Zinc is the composition of Regular Insulin, and the zinc in pancreas reduces to a half of normal contents, just has the possibility of diabetes; Zinc also has the effect promoting lymphopoiesis and mobility.During zn deficiencie, each system of whole body all can be adversely affected.According to " DRIs " standard that the 8th National Nutrient conference is passed through, it is 15 milligrams that human body zinc every day takes in recommended amounts, the diet formula of China resident is based on cereal, in cereal, the bioavailability of zinc is very low, be only 20-40%, eat purified diet if at ordinary times more, more easily cause zinc deficiency, so zinc supplementation is required concerning human body.In current zinc supplementation product, the absorption rate of zinc sulfate, Zinc-oxide-based inorganic zinc product is low, and has hormesis to stomach; And the organic zinc product of Zinc Gluconate, zinc glycyrrhizate class needs one after each meal, and may with feeling sick, the side effect such as constipation, unsuitable long-term taking.
Therefore, problem demanding prompt solution is become to the improvement of existing oral zinc reinforcing product.
summary of the invention
Given this, the invention provides inulin zinc and containing the oral liquid of inulin zinc, it is while zinc supplementation, can promote the absorption of zinc, solving the human body that exists in zinc supplementation product in the past cannot good absorption, causes the problems such as zinc matter waste.
One aspect of the present invention provides inulin zinc, it is characterized in that, is prepared from by following steps:
I) in reactor, adding 70 ~ 90 weight part concentration expressed in percentage by volumes is the ethanolic soln of 95%, then adds 100 weight part inulin and 68 ~ 88 parts by weight of sodium hydroxide successively, stirs, obtains mixing solutions;
Ii) will add the Monochloro Acetic Acid ethanolic soln that 95 ~ 140 weight part mass percentage concentration are 75 ~ 85% in above-mentioned mixing solutions, under keeping 45 ~ 55 DEG C of constant temperatures, stir 3 ~ 5 hours, leave standstill 1 ~ 3 hour, and remove supernatant liquid, throw out is used 95% washing with alcohol;
Iii) the throw out after washing with alcohol is dried under temperature is 75 ~ 85 DEG C of conditions, the throw out of drying and zinc lactate are reacted, obtained inulin zinc.
The present invention provides a kind of oral liquid containing inulin zinc on the other hand, and it is characterized in that, described oral liquid comprises: inulin zinc, buffer reagent, sweeting agent and water, and wherein, the content of inulin zinc is 2400 ~ 11000mg/L.
Preferably, the pH value of described oral liquid is 3.8 ~ 5.0.
Further preferably, described buffer reagent is lactic acid.
Further preferably, described sweeting agent is aspartame.
Inulin zinc provided by the invention, under first inulin molecules being placed in alkaline condition, conversion of hydroxyl is negative oxygen ion active centre, then, play etherification reaction with Monochloro Acetic Acid ethanolic soln, generate Carboxymethylinulin, finally, Carboxymethylinulin again with Zinc Ions Chelated, and then prepare inulin zinc.
Oral liquid containing inulin zinc provided by the invention, by adding of inulin zinc, while zinc supplementation, improves the absorption of zinc in human body oral disposition liquid, is of value to HUMAN HEALTH.
Inulin zinc provided by the invention and containing the oral liquid of inulin zinc, can strengthen the absorption of human body to zinc matter while zinc supplementation, has that zinc supplementation is effective, zinc supplementation promotes zinc-iron alloy solution simultaneously, benefits the advantages such as HUMAN HEALTH.
Embodiment
Below in conjunction with specific embodiment, the present invention is further explained, but is not limited to the present invention.
In order to solve the problem that zinc in the past blames to absorb, the invention provides a kind of inulin zinc, being prepared from by following steps:
I) in reactor, adding 70 ~ 90 weight part concentration expressed in percentage by volumes is the ethanolic soln of 95%, then adds 100 weight part inulin and 68 ~ 88 parts by weight of sodium hydroxide successively, stirs, obtains mixing solutions;
Ii) will add the Monochloro Acetic Acid ethanolic soln that 95 ~ 140 weight part mass percentage concentration are 75 ~ 85% in above-mentioned mixing solutions, under keeping 45 ~ 55 DEG C of constant temperatures, stir 3 ~ 5 hours, leave standstill 1 ~ 3 hour, and remove supernatant liquid, throw out is used 95% washing with alcohol;
Iii) the throw out after washing with alcohol is dried under temperature is 75 ~ 85 DEG C of conditions, the throw out of drying and zinc lactate are reacted, obtained inulin zinc.
Inulin described in the present invention is commercially available, and being take fructose as the polymkeric substance of unit, is a kind of good water-soluble dietary fibre, itself has the physiological function improved intestinal microenvironment, promote zinc-iron alloy solution.C-3, C-4 and C-6 in inulin fructose unit there is free hydroxyl, substitution reaction can occur.Inulin molecules introduces charged group, can with Zinc Ions Chelated, and then prepare Carboxymethylinulin zinc, i.e. inulin zinc.Inulin zinc is not digested in stomach and small intestine, can arrive colon smoothly, and at colonic by bifidobacterium fermentation, inulin zinc is degraded in fermentation, discharges zinc, thus makes zinc effectively be absorbed.In addition, the acid produced by fermenting reduces pH value l ~ 2 unit of colon, the solubleness of the mineral substance such as zinc (biological effectiveness) is improved greatly, adds the absorbed dose of human body to zinc, promotes Metabolism of Normal, improves body immunity, be applicable to all kinds of crowd.
Wherein, in whole preparation process:
I) step is basification stage, and conversion of hydroxyl, under the alkaline condition of sodium hydroxide, can be negative oxygen ion active centre by inulin molecules.Wherein with concentration expressed in percentage by volume be the ethanolic soln of 95% as reaction medium, can reaction be made evenly, and more easily to remove in subsequent step;
Ii) step is etherification stage, plays etherification reaction with Monochloro Acetic Acid, generates Carboxymethylinulin;
Iii) step is chelation stage, Carboxymethylinulin and Zinc Ions Chelated, and then prepares inulin zinc.
In order to the zinc matter solving oral zinc reinforcing product existence is in the past not easy to the problem of absorption of human body, present invention also offers a kind of oral liquid containing inulin zinc, this oral liquid comprises: inulin zinc, buffer reagent, sweeting agent and water, and wherein, the content of inulin zinc is 2400-11000mg/L.
Oral liquid in the present invention, not digested in stomach and small intestine by inulin zinc, colon can be arrived smoothly, at colonic by bifidobacterium fermentation, discharge short chain fatty acid and zine ion.Short chain fatty acid can promote that colon epithelial cell is bred, and reduces gut pH, is conducive to the absorption of zinc.Organic acid is absorbed in small intestine, and inulin zinc is absorbed at colonic, the organic acid reaction in zine ion and food effectively can be avoided like this to form indissoluble salt, add the absorbed dose of human body to zinc, promotes Metabolism of Normal, improves body immunity.Wherein add lactic acid as buffer reagent, the pH value of the adjustable system of lactic acid, guarantee system stay in grade, while providing tart flavour, has preservative activity concurrently.In addition, add aspartame as sweeting agent, aspartame is a kind of widely used low calorie sweetener, has the advantages that unlikely carious tooth, sweet taste are pure; Aspartame is the most stable in PH 3 ~ 5 scope, is applicable to the acidity system of oral liquid of the present invention completely.Because buffer reagent and sweeting agent have to this oral liquid the effect that taste regulates, therefore, its consumption can change according to the different setting of taste, and its consumption can be determined within the specific limits.
And inulin zinc is for be prepared from according to the method described above, buffer reagent, sweeting agent are all commercially available, and water is underground water, mineral water or deionized water.
Wherein, the pH value of this oral liquid is preferably 3.8 ~ 5.0, when it is in this acid range, is most suitable for the absorption of human body.
Preferred buffer reagent is lactic acid, and sweeting agent is aspartame.
Should the oral liquor containing inulin zinc be that moiety inulin zinc, buffer reagent, sweeting agent and water are mixed.
Embodiment 1
An oral liquid containing inulin zinc, be mixed by inulin zinc, lactic acid, aspartame and water, wherein, the content of inulin zinc is 2400mg/L, and the content of lactic acid (by weight) is 0.5%, and the content of aspartame (by weight) is 0.3%.
Embodiment 2
An oral liquid containing inulin zinc, be mixed by inulin zinc, lactic acid, aspartame and water, wherein, the content of inulin zinc is 11000mg/L, and the content of lactic acid (by weight) is 1.2%, and the content of aspartame (by weight) is 0.5%.
Embodiment 3
An oral liquid containing inulin zinc, be mixed by inulin zinc, lactic acid, aspartame and water, wherein, the content of inulin zinc is 5000mg/L, and the content of lactic acid (by weight) is 0.75%, and the content of aspartame (by weight) is 0.39%.
Embodiment 4
An oral liquid containing inulin zinc, be mixed by inulin zinc, lactic acid, aspartame and water, wherein, the content of inulin zinc is 8000mg/L, and the content of lactic acid (by weight) is 1.0%, and the content of aspartame (by weight) is 0.43%.
Embodiment 5
Clinical testing data of the present invention is as follows:
1, trial drug
(1) inulin zinc oral liquid: the inulin zinc oral liquid using preparation in embodiment 1 ~ 4 respectively, every bottle amasss 10ml(containing inulin zinc 24mg/ bottle).
(2) not containing the common zinc oral liquid of inulin zinc: every bottle amasss 10ml(zinc-containing substance 24mg/ bottle).
2, study subject
Infant is in the growth quick phase, relatively high to the demand of zinc, is ZD high risk population, therefore the study subject of test is defined as the children that the age is 3 ~ 5 years old.
This experiment comprises 60 study subjects altogether, 3 ~ 5 years old age, male or female, and voluntary participation under guardian agrees to also signs Written informed consent.Random packet; To the summary of these study subjects in table 1.Test-results is: the experimenter of (n=60) 100% completes test.
Subject's basic condition tested by table 1.
3, test method
(1) requirement is taken: to accept once a day all experimenters of duration of test, the test dose of each a bottle.Test period is 6 months, and many foods contained zinc diet and kept appropriate exercise amount period.Wherein can daily any one inulin zinc oral liquid in embodiment 1 ~ 4 in first group.
(2) measuring method:
In current human body, the measuring method of trace element zinc is a lot, and zinc and two kinds, blood zinc are sent out in relatively more conventional the having being applicable to children.Consider that sending out zinc measurement method affects comparatively large by externalities, the measuring method of this test and Selection blood zinc.
Adopt chemiluminescence determination serum zinc content, sample mode is gather venous blood on an empty stomach early morning.
4, result
First group: before and after experiment, subject's blood zinc on average increases by 4.3%.And do not find any untoward reaction.
Second group: before and after experiment, subject on average increases by 3.4%.And do not find any untoward reaction.
From the above results, take first group of inulin zinc oral liquid compared with second group that takes the common zinc oral liquid not containing inulin zinc, the blood zinc increase per-cent of first group of subject is more, it is more obvious that inulin zinc oral liquid zinc supplementation effect is taken in explanation, and inulin zinc oral liquid has the effect promoting zinc-iron alloy solution.
Claims (5)
1. an inulin zinc, is characterized in that, is prepared from by following steps:
I) in reactor, adding 70 ~ 90 weight part concentration expressed in percentage by volumes is the ethanolic soln of 95%, then adds 100 weight part inulin and 68 ~ 88 parts by weight of sodium hydroxide successively, stirs, obtains mixing solutions;
Ii) will add the Monochloro Acetic Acid ethanolic soln that 95 ~ 140 weight part mass percentage concentration are 75 ~ 85% in above-mentioned mixing solutions, under keeping 45 ~ 55 DEG C of constant temperatures, stir 3 ~ 5 hours, leave standstill 1 ~ 3 hour, and remove supernatant liquid, throw out is used 95% washing with alcohol;
Iii) the throw out after washing with alcohol is dried under temperature is 75 ~ 85 DEG C of conditions, the throw out of drying and zinc lactate are reacted, obtained inulin zinc.
2. the oral liquid containing inulin zinc, it is characterized in that, described oral liquid comprises: inulin zinc, buffer reagent, sweeting agent and water, and wherein, the content of inulin zinc is 2400 ~ 11000mg/L.
3., according to the oral liquid containing inulin zinc described in claim 2, it is characterized in that: the pH value of described oral liquid is 3.8 ~ 5.0.
4., according to the oral liquid containing inulin zinc described in claim 2, it is characterized in that: described buffer reagent is lactic acid.
5., according to the oral liquid containing inulin zinc described in claim 2, it is characterized in that: described sweeting agent is aspartame.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410444786.6A CN104231099B (en) | 2014-09-03 | A kind of inulin zinc and the oral liquid containing inulin zinc |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410444786.6A CN104231099B (en) | 2014-09-03 | A kind of inulin zinc and the oral liquid containing inulin zinc |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104231099A true CN104231099A (en) | 2014-12-24 |
| CN104231099B CN104231099B (en) | 2017-01-04 |
Family
ID=
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102160664A (en) * | 2011-02-21 | 2011-08-24 | 苟春虎 | Nutritious drink for children |
| CN102526009A (en) * | 2012-02-21 | 2012-07-04 | 常熟市方塔涂料化工有限公司 | Zinc calcium gluconate oral solution |
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102160664A (en) * | 2011-02-21 | 2011-08-24 | 苟春虎 | Nutritious drink for children |
| CN102526009A (en) * | 2012-02-21 | 2012-07-04 | 常熟市方塔涂料化工有限公司 | Zinc calcium gluconate oral solution |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vince et al. | The effect of lactulose, pectin, arabinogalactan and cellulose on the production of organic acids and metabolism of ammonia by intestinal bacteria in a faecal incubation system | |
| Jali et al. | Efficacy of value added foxtail millet therapeutic food in the management of diabetes and dyslipidamea in type 2 diabetic patients | |
| CN102160614B (en) | Compound preparation for improving immunity of human bodies and enhancing bone density and application thereof | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN103284039A (en) | Weight-reducing composition and preparation method thereof | |
| Geboes et al. | The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon | |
| EP2271367B1 (en) | Mineral absorption accelerator and iron deficiency anemia improver or food composition | |
| CN108024981A (en) | A kind of carboxylic acid composition for treating nephrotic | |
| CN104620853B (en) | A kind of breeding method of Se-rich lucid ganoderma conidia powder or fructification | |
| CN106359849B (en) | A kind of fermented feed of the microelement containing humic acid chelating and preparation method thereof | |
| CN103054127A (en) | Cellulose effervescent tablet with weight reducing function | |
| Matsuda et al. | Morphology and physiology of colobine digestive tracts | |
| Jonker et al. | 13-Week oral toxicity study with isomaltulose (Palatinose®) in rats | |
| Johnston et al. | A preliminary evaluation of the safety and tolerance of medicinally ingested vinegar in individuals with type 2 diabetes | |
| Kahraman et al. | The effect of vinegar on postprandial glycemia: does the amount matter? | |
| CN104231099B (en) | A kind of inulin zinc and the oral liquid containing inulin zinc | |
| CN103053807B (en) | Water-soluble composite vitamin preparation and preparation method thereof | |
| CN105053773A (en) | Black garlic fructo-oligosaccharide tablet and preparation method thereof | |
| CN104231099A (en) | Inulin zinc and oral liquid containing same | |
| CN104262499A (en) | Zinc fructooligosaccharides and oral liquid containing same | |
| CN105995119A (en) | High-copper feed for establishing HLD (hepatolenticular degeneration) animal model and preparation method of high-copper feed | |
| CN104223067A (en) | Inulin calcium and oral solution containing inulin calcium | |
| CN104546894B (en) | Application of the inulin in the property hyperoxaluria of intestines source | |
| CN106820161A (en) | Aloe mineral crystalline substance and preparation method thereof | |
| RU2554767C2 (en) | Medication for stimulation of metabolic processes and growth activity of calves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20170330 Granted publication date: 20170104 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20220130 Granted publication date: 20170104 |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20220130 Granted publication date: 20170104 |